bpc-157 + tb-500 quicksilver scientific Research Peptide Set Introducing: Liposomal BPC-157 + TB-500

Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health

Dosage at a Glance Administer by subcutaneous injection only

Sergey Terushkin, MD, FACS Florida Surgery & Weight Loss Center is located at 1911 Harrison Street in Hollywood, FL and provides medical weight loss, peptide therapy, wellness medicine, bariatric care, and provider-guided treatment programs for eligible patients

(accessed Sep 27, 2019)